TNGX

Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. It is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. It is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.

Wall Street analysts forecast TNGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNGX is 13.00 USD with a low forecast of 11.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Tango Therapeutics Inc revenue for the last quarter amounts to 53.81M USD, increased 363.61 % YoY.

Tango Therapeutics Inc. EPS for the last quarter amounts to 0.13 USD, decreased -148.15 % YoY.

Tango Therapeutics Inc (TNGX) has 155 emplpoyees as of December 16 2025.

Today TNGX has the market capitalization of 1.23B USD.